Introduction: In non-small cell lung cancer (NSCLC), immunotherapy is one of today's most important and ground-breaking systemic treatments, mainly represented by antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death protein 1 or ligand 1 (PD-1/PD-L1). ...
Explore IMFINZI® (durvalumab) or IMJUDO® (tremelimumab-actl), an immunotherapy for adults with certain types of NSCLC, SCLC, advanced BTC, unresectable HCC, and dMMR endometrial cancer.
Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress. News October 17, 2024 3 min read Save Timing of immunotherapy influences benefit in limited-stage small cell lung...
近几十年, SCLC进步缓慢, IMpower133研究开启了SCLC一线化疗联合免疫治疗(immunotherapy, IO)的序幕, CASPIAN再次奠定了PD-L1抑制剂在广泛期SCLC一线治疗的地位。 关于CASPIAN研究设计, 与其它一线SCLC试验略有不同, 应该说更加反应了真实世界...
IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, NSCLC, ES-SCLC, and advanced or recurrent endometrial cancer.
atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iad...
[5] Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy: (Trends in Biochemical Sciences 43, 1014-1032; 2018). Trends Biochem Sci. 2019 Jun;44(6):557. doi: 10.1016/...
Dave Fredrickson, Executive Vice President, Oncology Business Unit,AstraZeneca, said: “This approval for IMFINZI marks a breakthrough for patients with limited-stage small cell lung cancer, allowing them to receive immunotherapy for the first time. The ADRIATIC trial showed an improvement in medi...
1.https://www.astrazeneca.com/media-centre/press-releases/2019/imfinzi-and-imfinzi-plus-tremelimumab-delayed-disease-progression-in-phase-iii-poseidon-trial-for-1st-line-treatment-of-stage-iv-non-small-cell-lung-cancer.html 2. Martinez P, Peters S, Stammers T, et al. Immunotherapy for the ...
Adding immunotherapy in the form of durvalumab to chemotherapy improves overall survival in patients with extensive-stage small cell lung cancer, according to research presented today at the IASLC 2019 World Conference on Lung Cancer hosted by the Intern